Document is current
Any future updates will be listed below
-
Authors
Murota, Hiroyuki
Nakahara, Takeshi
Noto, Shinichi
Matsukawa, Miyuki
Takeda, Hiroe
Toda, Rikiya
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 27 October 2024
Accepted: 16 December 2024
First Online: 15 January 2025
Declarations
:
: Hiroyuki Murota, has received consulting fees and/or speaker honoraria from Maruho Co., Ltd., Sanofi K.K., Pfizer Japan Inc., Torii Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Takeshi Nakahara has received consulting fees and/or speaker honoraria from Mitsubishi Tanabe Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Maruho, Sanofi, AbbVie, Eli Lilly Japan, Sun Pharma and Otsuka Pharmaceutical. Shinichi Noto has received speaker honoraria from Otsuka Pharmaceutical. Miyuki Matsukawa, Hiroe Takeda and Rikiya Toda are employees of Otsuka Pharmaceutical Co., Ltd.
: This study used secondary, anonymized data provided by DeSC. Therefore, no additional individual-level informed consent was obtained for conducting this study. The study protocol was approved by the Ethics Committee of Otsuka Pharmaceutical Co., Ltd. Research and Development Division, Research Ethics Committee (application and approval No. 221013). The questionnaire survey was conducted by DeSC in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan and the Declaration of Helsinki.
